LENZ vs TNXP
LENZ: LENZ Therapeutics is a commercial-stage ophthalmology company marketing VIZZ, a first-of-its-kind, once-daily aceclidine-based eye drop for treating presbyopia. TNXP: A commercial-stage biopharmaceutical company focused on CNS, immunology, and infectious disease therapies, headlined by its FDA-approved fibromyalgia treatment, TONMYA.
Side-by-side fundamentals
| Metric | LENZ | TNXP | Edge |
|---|---|---|---|
| Price as of 2026-10-30 close | $3.05 | $5.10 | |
| Market cap | $96M | $87M | |
| Net margin FY2025, SEC XBRL | -430.3% | -946.2% | LENZ higher |
| Operating margin FY2025, SEC XBRL | -477.5% | -959.1% | LENZ higher |
| ROE FY2025, SEC XBRL | -28.9% | -50.6% | LENZ higher |
| ROA FY2025, SEC XBRL | -26.8% | -44.7% | LENZ higher |
| Debt / equity 0 — no debt reported, balance sheet 2026-06-30 | 0.00 | n/a | |
| Revenue growth (YoY) FY2025, SEC XBRL | n/a | +29.9% | |
| Revenue CAGR (3y) SEC XBRL | n/a | +29.9% | |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 1.67 | 1.07 | |
| 1-year return as of 2026-10-30 close | -90.0% | -71.8% | TNXP higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-30.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.